Nivolumab

Thousands of patients will benefit from a new cancer jab for more than a dozen types of the disease, with the NHS the first in Europe to offer the new injection. The health service is rolling out an injectable form of immunotherapy, nivolumab, which means patients can receive their fortnightly or mo

Hey everyone. I know this update has taken longer than expected, but a lot has happened and I wanted to wait to post until now after an eventful month. First off, I would like to say that rapamycin really did save my life. I was about to give up when I tried it, and it was the miracle I needed to b

​ Given everything that’s going on with the movement against shorting, I present HTBX. \~25% avg daily short interest([https://fintel.io/ss/us/htbx](https://fintel.io/ss/us/htbx)), with a float of 21.75M shares. Forget about GME, AMC, NOK, etc. No institution should short a company that’s

Here’s my complete DD on my favorite play right now, HTBX. HTBX is a preclinical bio flush with cash. I’m going to give a basic background on the company, go over financials, go through the upcoming catalysts, include an expected value model on one of the drugs, and with all this seemingly good info

Background info Male, 35 years old, diagnosed 25th July 2025 Stage 4 Esophageal Cancer with liver mets Prognosis 12-16 months to live Current Treatment: Nivolumab and Folfox Intending to fight it and live for the next 60 years to die old toothless and in bed How many survivors out there that can rea

Hi everyone, I’m looking for advice or shared experiences. My husband is 31 years old and has stage 4 melanoma (BRAF negative) that has spread (including to bone). He is now bed bound, in significant pain, and confused at times (he had an episode of unresponsiveness recently). MRI, CT, EEG, X-rays a

A paper published in *Cancers*, a journal with a respectable impact factor (5.2), found that medical marijuana & immunotherapy was a potentially lethal combination (1). This manuscript, and a similar earlier one by the same lab (2), have been cited hundreds of times including by some clinical p

We have a patient coming up for CAR-T who is currently getting nivolumab and brentuximab. In my researching today, I found that T-cell lytic drugs should be held 8 weeks prior to collection and that immune targeted therapies should be held for "several half lives or 1 month". With the half life of n